Next Generation mRNA Therapies Post COVID-19 with Jacob Becraft of Strand Therapeutics

Bringing back the Mammoth: featuring Colossal Biosciences’ CEO Ben Lamm and Scientist Christopher Mason

The DeciBio team interviews Colossal Biosciences’ co-founder and CEO, Ben Lamm and Colossal Biosciences' Scientific Advisor and Professor of Computational Genomics, Christopher Mason, to discuss the science behind Colossal's mission to de-extinct the woolly mammoth and furthermore, the implications their advancements in genetic engineering and embryology, may have on human health applications.

Accelerating Precision Medicine Through Biomarker Testing: A DeciBio Expert Panel Discussion

How do you maximize clinical trial samples, especially as we face a growing need for biomarker testing? Learn more about these precision medicine questions as one of our experts interviews a panel of leaders from pharma, clinical testing, and hospital settings.

Liquid Biopsy 2023 Forecast: Clinicians' Perspectives

Clinicians from top medical centers in the United States share their predictions for the Liquid Biopsy (LBx) industry in 2023. Our specialists, including Partner Andrew Aijian, chime in with LBx trends, adoption, and activities, based on our work in the space.

Next Generation mRNA Therapies Post COVID-19 with Jacob Becraft of Strand Therapeutics

On this episode, Alex Amram and Joe Daccache interview special guest, Jacob Becraft the CEO and co-founder of Strand https://www.strandtx.com/Therapeutics— a company leveraging synthetic biology to create the next-generation of messenger RNA (mRNA) therapeutics using a platform of programmable, precise, and multi-functional mRNAs through the implementation of genetic logic circuits and other genomic features.